Affect regulation, stimulant use, and viral load among HIV-positive persons on anti-retroviral therapy

Psychosomatic Medicine

Volumn 69, Issue 8, 2007, Pages 785-792

  Carrico, Adam W ^a   Johnson, Mallory O ^b   Moskowitz, Judith T ^c   Neilands, Torsten B ^b   Morin, Stephen F ^b   Charlebois, Edwin D ^b   Steward, Wayne T ^b   Remien, Robert H ^d   Wong, F Lennie ^e   Rotheram Borus, Mary Jane ^e   Lightfoot, Marguerita A ^e   Chesney, Margaret A ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Adherence; Affect; Cocaine; Depression; HIV; Methamphetamine

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AFFECT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; BEHAVIOR CONTROL; BEHAVIOR THERAPY; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SUBSTANCE ABUSE; SYMPTOM; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; AFFECT; AGED; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM STIMULANTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SUBSTANCE-RELATED DISORDERS; VIRAL LOAD;

EID: 37349103385     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/PSY.0b013e318157b142     Document Type: Article

References (52)

1. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry 2003;54:216-26.
2. Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, Turner BJ, Eggan F, Beckman R, Vitiello B, Morton SC, Orlando M, Bozzette SA, Ortiz-Barron L, Shapiro M. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry 2001;58:721-8.
3. Leserman J. HIV disease progression: depression, stress, and possible mechanisms. Biol Psychiatry 2003;54:295-306.
4. Antoni MH, Carrico AW, Duran RE, Spitzer S, Penedo F, Ironson G, Fletcher MA, Klimas N, Schneiderman N. Randomized clinical trial of cognitive behavioral stress management on human immunodeficiency virus viral load in gay men treated with highly active antiretroviral therapy. Psychosom Med 2006;68:143-51.
5. Ironson G, O'Cleirigh C, Fletcher MA, Laurenceau JP, Balbin E, Klimas N, Schneiderman N, Solomon G. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med 2005;67:1013-21.
6. Adler NE, Horowitz M, Garcia A, Moyer A. Additional validation of a scale to assess positive states of mind. Psychosom Med 1998;60:26-32.
7. Folkman S. Positive psychological states and coping with severe stress. Soc Sci Med 1997;45:1207-21.
8. Carrico AW, Ironson G, Antoni MH, Lechner SC, Duran RE, Kumar M, Schneiderman N. A path model of the effects of spirituality on depressive symptoms and 24-h urinary-free cortisol in HIV-positive persons. J Psychosom Res 2006;61:51-8.
9. Bower JE, Kemeny ME, Taylor SE, Fahey JL. Cognitive processing, discovery of meaning, CD4 decline, and AIDS-related mortality among bereaved HIV-seropositive men. J Consult Clin Psychol 1998;66:979-86.
10. Ickovics JR, Milan S, Boland R, Schoenbaum E, Schuman P, Vlahov D. Psychological resources protect health: 5-year survival and immune function among HIV-infected women from four US cities. AIDS 2006;20:1851-60.
11. Moskowitz JT. Positive affect predicts lower risk of AIDS mortality. Psychosom Med 2003;65:620-6.
12. Carrico AW, Antoni MH, Young L, Gorman JM. Psychoneuroimmunology and HIV. In: Cohen MA, Gorman, JM, editors. Comprehensive Textbook of AIDS Psychiatry. Oxford: Oxford University Press; 2008:27-38.
13. DiClemente CC. Addiction and Change: How Addictions Develop and Addicted People Recover. New York: Guilford Press; 2003.
14. Gifford E, Humphreys K. The psychological science of addiction. Addiction 2007;102:352-61.
15. Gifford EV, Ritsher JB, McKellar JD, Moos RH. Acceptance and relationship context: a model of substance use disorder treatment outcome. Addiction 2006;101:1167-77.
16. Carrico AW, Gifford EV, Moos RH. Spirituality/religiosity promotes acceptance-based responding and 12-step involvement. Drug Alcohol Depend 2007;89:66-73.
17. Morgenstern J, Labouvie E, McCrady BS, Kahler CW, Frey RM. Affiliation with alcoholics anonymous after treatment: a study of its therapeutic effects and mechanisms of action. J Consult Clin Psychol 1997;65:768-77.
18. Baker TB, Piper ME, McCarthy DE, Majeskie MR, Fiore MC. Addiction motivation reformulated: an affective processing model of negative reinforcement. Psychol Rev 2004;111:33-51.
19. Semple SJ, Patterson TL, Grant I. Motivations associated with methamphetamine use among HIV+ men who have sex with men. J Subst Abuse Treat 2002;22:149-56.
20. Levine AJ, Hinkin CH, Castellon SA, Mason KI, Lam MN, Perkins A, Robinet M, Longshore D, Newton T, Myers H, Durvasula RS, Hardy DJ. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav 2005;9:355-62.
21. Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, Schoenbaum EE. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002;17:377-81.
22. Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, Myers HF, Longshore D. Drug Use and Medication Adherence among HIV-1 Infected Individuals. AIDS Behav 2007;11:185-94.
23. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I. Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 2003;188:1820-6.
24. Peck JA, Shoptaw S, Rotheram-Fuller E, Reback CJ, Bierman B. HIV-associated medical, behavioral, and psychiatric characteristics of treatment-seeking, methamphetamine-dependent men who have sex with men. J Addict Dis 2005;24:115-32.
25. Colfax GN, Vittinghoff E, Grant R, Lum P, Spotts G, Hecht FM. Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance. AIDS 2007;21:239-41.
26. Wong W, Chaw JK, Kent CK, Klausner JD. Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003. Sex Transm Dis 2005;32:458-63.
27. Remien RH, Exner TM, Morin SF, Ehrhardt AA, Johnson MO, Correale J, Marhefka S, Kirshenbaum SB, Weinhardt LS, Rotheram-Borus MJ, Catz SL, Gore-Felton C, Chesney MA, Kelly J. Medication adherence and sexual risk behavior among HIV-infected adults: implications for transmission of resistant virus. AIDS Behav 2007;11:663-675.
28. Makisumi T, Yoshida K, Watanabe T, Tan N, Murakami N, Morimoto A. Sympatho-adrenal involvement in methamphetamine-induced hyperthermia through skeletal muscle hypermetabolism. Eur J Pharmacol 1998;363:107-12.
29. Kobilka B. Adrenergic receptors as models for G protein-coupled receptors. Annu Rev Neurosci 1992;15:87-114.
30. Cole SW, Korin YD, Fahey JL, Zack JA. Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J Immunol 1998;161:610-6.
31. Cole SW, Naliboff BD, Kemeny ME, Griswold MP, Fahey JL, Zack JA. Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity. Proc Natl Acad Sci U S A 2001;98:12695-700.
32. Johnson MO, Catz SL, Remien RH, Rotheram-Borus MJ, Morin SF, Charlebois E, Gore-Felton C, Goldsten RB, Wolfe H, Lightfoot M, Chesney MA. Theory-guided, empirically supported avenues for intervention on HIV medication nonadherence: findings from the healthy living project. AIDS Patient Care STDS 2003;17:645-56.
33. Healthy Living Project Team. Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: the healthy living project randomized controlled study. J Acquir Immune Defic Syndr 2007;44:213-21.
34. Turner CF, Ku L, Rogers SM, Lindberg LD, Pleck JH, Sonenstein FL. Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science 1998;280:867-73.
35. Moskowitz JT, Folkman S, Acree M. Do positive psychological states shed light on recovery from bereavement? Findings from a 3-year longitudinal study. Death Stud 2003;27:471-500.
36. Beck AT, Steer RA, Ball R, Ranieri W. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588-97.
37. Kalichman SC, Rompa D, Cage M. Distinguishing between overlapping somatic symptoms of depression and HIV disease in people living with HIV-AIDS. J Nerv Ment Dis 2000;188:662-70.
38. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient care committee & adherence working group of the outcomes committee of the adult AIDS clinical trials group (AACTG). AIDS Care 2000;12:255-66.
39. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav 2006;10:227-45.
40. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006;43:939-41.
41. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007;4:65-72.
42. Muthén LK, Muthén MB. MPlus: Statistical Analysis With Latent Variables. Los Angeles: Muthén and Muthén; 2004.
43. Hu L, Bentler PM. Fit indices in covariance structure modeling: Sensitivity to underparameterized model misspecification. Psychol Methods 1998;112:424-453.
44. Kline RB. Principles and Practice of Structural Equation Modeling. New York: Guilford Press; 1998.
45. Koblin BA, Husnik MJ, Colfax G, Huang Y, Madison M, Mayer K, Barresi PJ, Coates TJ, Chesney MA, Buchbinder S. Risk factors for HIV infection among men who have sex with men. AIDS 2006;20:731-9.
46. Antoniou T, Tseng AL. Interactions between recreational drugs and antiretroviral agents. Ann Pharmacother 2002;36:1598-613.
47. Kopnisky KL, Bao J, Lin YW. Neurobiology of HIV, psychiatric and substance abuse comorbidity research: workshop report. Brain Behav Immun 2007;21:428-41.
48. Llabre MM, Weaver KE, Duran RE, Antoni MH, McPherson-Baker S, Schneiderman N. A measurement model of medication adherence to highly active antiretroviral therapy and its relation to viral load in HIV-positive adults. AIDS Patient Care STDS 2006;20:701-11.
49. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, Harrigan PR, Parkin N, Deeks SG. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006;20:223-31.
50. Sorensen JL, Haug NA, Delucchi KL, Gruber V, Kletter E, Batki SL, Tulsky JP, Barnett P, Hall S. Voucher reinforcement improves medication adherence in HIV-positive methadone patients: a randomized trial. Drug Alcohol Depend 2007;88:54-63.
51. Carroll KM, Rawson RA. Relapse prevention for stimulant dependence. In: Marlatt GA, Donovan DM, editors. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors. New York: Guilford Press; 2005:130-50.
52. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Top HIV Med 2003;11:185-98.